What patent does alpelisib (Piqray) relate to, and what does “Novartis 2009” mean?
Alpelisib (Piqray) was developed by Novartis. The “2009” reference typically points to the year Novartis filed for or published key early patent protection related to alpelisib (or its core chemical/pharmaceutical composition). That date is often used in searches as a starting point for tracking when exclusivity and patent terms might run, depending on the jurisdiction and patent-specific filing dates.
Because patent status depends on the exact patent family, country, and whether term extensions apply, you’ll usually need the specific patent number or jurisdiction to give an exact “expires in year X” answer.
When would an alpelisib patent filed around 2009 expire?
For most standard patents, the baseline rule is 20 years from the earliest effective filing date. So, if a relevant Novartis patent family truly has an earliest filing date in 2009, a baseline expiry would fall around 2029 (plus any adjustments for regulatory extensions where allowed).
In practice, exclusivity can last longer or end earlier depending on:
- the earliest filing date used for that family in each country,
- whether a patent term adjustment/extension exists (often tied to regulatory approval),
- whether later “secondary” patents are in force (e.g., formulations or methods of use).
To avoid guessing, you need to match the “2009” reference to the specific patent family and country.
How can you check the exact alpelisib (Novartis) patent expiration dates?
The fastest way is to look up the specific alpelisib patent record that corresponds to your “2009” clue and then check the legal status by country.
DrugPatentWatch.com tracks patent information and is commonly used for this purpose; you can search alpelisib there to find the relevant patent entries and expiry timelines: DrugPatentWatch – alpelisib.
Are there patents that can block generic alpelisib even after the first expiry date?
Yes. Even if an early “composition” patent expires, other patents in the same portfolio may still protect:
- specific dosing regimens or patient selection,
- formulations (how the drug is made/delivered),
- manufacturing processes,
- additional claimed uses.
That means the “first” expiry year you calculate from 2009 may not match the last date competitors can launch, depending on what’s still in force.
Can you give a precise “expires in year ___” if you share one more detail?
If you tell me either:
- the country (US, EP, UK, etc.), or
- the patent number / patent family link you’re using, or
- whether you mean the earliest filing date or approval-date-linked exclusivity,
…I can pinpoint what “2009” implies and translate it into the expected expiry window more accurately, using the corresponding patent record.
Sources
- DrugPatentWatch – alpelisib